Expertise in
9
conditions

Jean-yves Y. Pierga

Department Of Head And Neck Surgery, 
Paris, FR 
Expertise in
9
conditions
Department Of Head And Neck Surgery, 
Paris, FR 

Overview

Jean-yves Pierga practices practicing medicine in Paris, France.

Pierga is highly rated in 9 conditions, according to our data. Their clinical expertise encompasses Breast Cancer, Inflammatory Breast Cancer, Triple-Negative Breast Cancer, HER2 Negative Breast Cancer, and Mastectomy.

They are actively involved in clinical research, co-authoring 240 peer reviewed articles and participating in 10 clinical trials.

Locations

Department Of Head And Neck Surgery, Paris, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
Enrollment Status: Active_not_recruiting
Publish Date: June 22, 2026
Intervention Type: Drug
Study Drugs: LY3484356, Abemaciclib, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor
Study Phase: Phase 1
A National, Multicenter, Randomized Controlled Trial to Assess the Efficacy of a Physical Activity Program to Improve Quality of Life and Reduce Fatigue in Women With Metastatic Breast Cancer
A National, Multicenter, Randomized Controlled Trial to Assess the Efficacy of a Physical Activity Program to Improve Quality of Life and Reduce Fatigue in Women With Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: May 04, 2026
Intervention Type: Device
Study Phase: Not Applicable
Prospective Construction and Validation of a Prognostic Score to Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From a Third Line Chemotherapy in Terms of Overall Survival
Prospective Construction and Validation of a Prognostic Score to Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From a Third Line Chemotherapy in Terms of Overall Survival
Enrollment Status: Completed
Publish Date: April 17, 2026
Intervention Type: Other
Study Phase: Phase 4
Efficacy of Regorafenib as Maintenance Therapy in Non-adipocytic Soft Tissue Sarcoma Having Received First-line Doxorubicin-based Chemotherapy
Efficacy of Regorafenib as Maintenance Therapy in Non-adipocytic Soft Tissue Sarcoma Having Received First-line Doxorubicin-based Chemotherapy
Enrollment Status: Completed
Publish Date: March 18, 2026
Intervention Type: Drug
Study Drug: Regorafenib
Study Phase: Phase 2
Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation (CHACRY-1501)
Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation (CHACRY-1501)
Enrollment Status: Active_not_recruiting
Publish Date: March 18, 2026
Intervention Type: Procedure
Study Phase: Not Applicable
A Prospective Multicenter Open-label, Randomized Phase II Study of Pembrolizumab in Combination With Neoadjuvant EC-Paclitaxel Regimen in HER2-negative Inflammatory Breast Cancer.
A Prospective Multicenter Open-label, Randomized Phase II Study of Pembrolizumab in Combination With Neoadjuvant EC-Paclitaxel Regimen in HER2-negative Inflammatory Breast Cancer.
Enrollment Status: Active_not_recruiting
Publish Date: September 12, 2025
Intervention Type: Drug
Study Drugs: Pembrolizumab Injection, Neoadjuvant EC-Paclitaxel Chemotherapy
Study Phase: Phase 2
Evaluation of Different Analysis Methods for Circulating Tumor Cells, Circulating Endothelial Cell, and Circulating Tumor DNA in Patient Followed for a Tumoral Pathology
Evaluation of Different Analysis Methods for Circulating Tumor Cells, Circulating Endothelial Cell, and Circulating Tumor DNA in Patient Followed for a Tumoral Pathology
Enrollment Status: Completed
Publish Date: August 08, 2025
Intervention Type: Procedure
Study Phase: Not Applicable
Analysis of Circulating Tumor Markers in the Blood
Analysis of Circulating Tumor Markers in the Blood
Enrollment Status: Completed
Publish Date: October 01, 2024
Intervention Type: Biological, Procedure, Other
Study Phase: Not Applicable
A Multicenter, Randomised, Open-label Phase II Study to Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
A Multicenter, Randomised, Open-label Phase II Study to Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
Enrollment Status: Unknown
Publish Date: February 12, 2024
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab, Capecitabine
Study Phase: Phase 2
Circulating Tumor DNA and Follow-up of BRCA1 Mutation Carriers (CirCa 01)
Circulating Tumor DNA and Follow-up of BRCA1 Mutation Carriers (CirCa 01)
Enrollment Status: Completed
Publish Date: January 31, 2024
Intervention Type: Procedure
Study Phase: Not Applicable
View 9 Less Clinical Trials

240 Total Publications

ASO Visual Abstract: Association Between Axillary Surgical Management and Survival in Patients with de novo Metastatic Breast Cancer.
ASO Visual Abstract: Association Between Axillary Surgical Management and Survival in Patients with de novo Metastatic Breast Cancer.
Journal: Annals of surgical oncology
Published: June 29, 2026

Frequently Asked Questions about Jean-yves Y. Pierga

Is Jean-yves Y. Pierga a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Jean-yves Y. Pierga is classified as an Elite expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jean-yves Y. Pierga participate in research or clinical trials?

Yes. Jean-yves Y. Pierga has published 240 articles and abstracts on conditions like Breast Cancer. You can view a list of Jean-yves Y. Pierga's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Pierga's expertise for a condition
ConditionClose
View All 12 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile